Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copper 64-DOTA-TLX 592

Next Previous
Drug Profile

Copper 64-DOTA-TLX 592

Alternative Names: 64Cu-DOTA-TLX592; 64Cu-TLX-592

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 30 May 2025 Copper 64-DOTA-TLX 592 is still in phase-I development in Prostate-cancer(Diagnosis) in Australia (IV, Injection) (NCT04726033)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in Australia (IV, Injection)
  • 21 May 2024 Pharmacokinetics and adverse events data from the phase I CUPID trial in Prostate cancer released by Telix Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top